MarketCap
Facebook
X
Telegram
GlaxoSmithKline plc Income Statement 2025-2011 | GSK
Brief overview of profit and loss at GlaxoSmithKline plc
The figures are compared over a five-year interval. The revenue attributed to GlaxoSmithKline plc moved from 24.4 billion pounds sterling to 32.7 billion pounds sterling between the two endpoints. The cumulative result was +34.1%, corresponding to roughly 6% per year. Sales increased steadily, although without strong acceleration.
The gross result shifted from 16.4 billion pounds sterling to 23.6 billion pounds sterling, or +44%. Revenue outpaced cost of revenue, allowing more sales to flow into gross profit. At the margin level, the figure shifted from 67.4% to 72.4%. The business retained more gross profit from each unit of revenue.
The operating result measured by EBITDA moved from 7.8 billion pounds sterling to 7.9 billion pounds sterling, or +1.9%. The operating result developed less favorably than sales. Comparing the endpoints gives EBITDA margins of 32% and 24.3%. A lower EBITDA share weakens the quality of the result.
Net income changed from 5.7 billion pounds sterling to 6.3 billion pounds sterling (+9.4%). Net earnings remained broadly steady over the period.
The market value of the business moved from 77.4 billion pounds sterling to 216 billion pounds sterling, or +179.3%. Valuation expanded much faster than the underlying results.
Financial takeaway
Positive developments coexist with areas of weakness. Key strengths include better sales economics, revenue expansion and net-income growth. The main areas of concern are a declining EBITDA margin. The next reporting periods will show whether revenue, margins, and final profitability can strengthen.
Annual Income Statement GlaxoSmithKline plc
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
216 B | 163 B | 171 B | 139 B | 206 B | 77.4 B | 88.8 B | 83.7 B | 70.9 B | 94.8 B | 99.7 B | 106 B | 126 B | 112 B | 113 B |
Shares |
4.05 B | 4.08 B | 4.05 B | 4.03 B | 5 B | 2.47 B | 2.47 B | 2.46 B | 2.44 B | 2.43 B | 2.42 B | 2.4 B | 2.42 B | 2.46 B | 2.51 B |
Historical Prices |
53.4 | 40.1 | 42.2 | 34.5 | 41.3 | 31.3 | 35.9 | 34 | 29 | 31.5 | 27.9 | 32.5 | 36.4 | 27.3 | 26.1 |
Net Income |
6.29 B | 2.95 B | 5.31 B | 15.6 B | 5.1 B | 5.75 B | 4.64 B | 3.62 B | 1.53 B | 912 M | 8.42 B | 2.76 B | 5.44 B | 4.56 B | 5.26 B |
Revenue |
32.7 B | 31.4 B | 30.3 B | 29.3 B | 24.7 B | 24.4 B | 33.8 B | 30.8 B | 30.2 B | 27.9 B | 23.9 B | 23 B | 26.5 B | 26.4 B | 27.4 B |
Cost of Revenue |
9.02 B | 9.05 B | 8.56 B | 9.55 B | 11.6 B | 11.7 B | 11.9 B | 10.2 B | 10.3 B | 9.29 B | 8.85 B | - | - | - | - |
Gross Profit |
23.6 B | 22.3 B | 21.8 B | 19.8 B | 16.5 B | 16.4 B | 21.9 B | 20.6 B | 19.8 B | 18.6 B | 15.1 B | 15.7 B | 17.9 B | 18.5 B | 20.1 B |
Operating Income |
7.93 B | 4.02 B | 6.74 B | 6.43 B | 6.2 B | 7.78 B | 6.96 B | 5.48 B | 4.09 B | 2.6 B | 10.3 B | - | - | - | - |
Interest Expense |
- | - | - | 912 M | 775 M | 888 M | - | - | - | - | - | - | - | - | - |
EBITDA |
7.93 B | 4.02 B | 6.74 B | 6.43 B | 6.2 B | 7.78 B | 6.96 B | 5.48 B | 4.09 B | 7.8 B | 4.26 B | 5.79 B | 7.32 B | 7.61 B | 8.64 B |
Operating Expenses |
- | - | - | - | - | 16.2 B | 34.2 B | 33.8 B | 33.6 B | 34.3 B | 20.8 B | 32.5 B | 31.1 B | 30.2 B | 31.4 B |
General and Administrative Expenses |
9.09 B | 11 B | 9.38 B | 8.37 B | 11 B | 11.5 B | 11.4 B | 9.92 B | 9.67 B | 9.37 B | 9.23 B | 8.25 B | 8.48 B | 8.74 B | 8.83 B |
All numbers in GBP currency
Quarterly Income Statement GlaxoSmithKline plc
| 2025-Q4 | 2024-Q4 | 2023-Q4 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
4.05 B | 4.08 B | 4.05 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
6.29 B | 2.95 B | 5.31 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
32.7 B | 31.4 B | 30.3 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
9.02 B | 9.05 B | 8.56 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
23.6 B | 22.3 B | 21.8 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
7.93 B | 4.02 B | 6.74 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
7.93 B | 4.02 B | 6.74 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
9.09 B | 11 B | 9.38 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in GBP currency
The income statement is one of the three key financial reports of a company GlaxoSmithKline plc (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Canada
China
USA
France
Singapore
Britain
Germany
Israel
Russia
Belgium
Niderland
Irlanda
